Lower urinary tract symptoms in elderly men: a simple yet comprehensive approach

被引:0
作者
Mancini, V. [1 ]
Balzarro, M. [2 ]
Illiano, E. [3 ]
Hoznek, A. [4 ]
Stallone, G. [5 ]
Carrieri, G. [1 ]
机构
[1] Univ Foggia, Dept Med & Surg Sci, Urol & Renal Transplantat Unit, Foggia, Italy
[2] AOUI Verona, Dept Urol, Verona, Italy
[3] Univ Perugia, Santa Maria Hosp Terni, Androl & Urogynecol Clin, Terni, Italy
[4] Henri Mondor Hosp, Dept Urol, Creteil, France
[5] Univ Foggia, Dept Med & Surg Sci, Nephrol Dialysis & Transplantat Unit, Foggia, Italy
来源
JOURNAL OF GERONTOLOGY AND GERIATRICS | 2018年 / 66卷 / 04期
关键词
Lower urinary tract symptoms; Benign prostatic hyperplasia; Prostate cancer; Bladder cancer; Detrusor overactivity; Detrusor underactivity; Elderly;
D O I
暂无
中图分类号
R4 [临床医学]; R592 [老年病学];
学科分类号
1002 ; 100203 ; 100602 ;
摘要
Lower urinary tract symptoms (LUTS) are common among elderly men and they may be linked to benign and malignant diseases of prostate and bladder, because of their shared inflammatory pathophysiology involving also the immune system. Actually the prostate should not be considered the only target of treatment in the management of male LUTS: it is necessary to treat bladder outlet obstruction, but also bladder and urethra. LUTS (particularly when refractory to therapy) often represent the starting point for identifying such conditions, requiring a specific and comprehensive approach. In this review, LUTS have been analysed with their association to the most frequent urological diseases as benign prostatic hyperplasia, prostate cancer, bladder cancer, and detrusor overactivity/underactivity, in a complex system of the elderly men.
引用
收藏
页码:245 / 252
页数:8
相关论文
共 106 条
  • [1] Abouassaly R, 2011, CAMPBELL WALSH UROLO, P2708
  • [2] Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
  • [3] Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)
    Abrams, Paul
    Kelleher, Con
    Staskin, David
    Rechberger, Tomasz
    Kay, Richard
    Martina, Reynaldo
    Newgreen, Donald
    Paireddy, Asha
    van Maanen, Rob
    Ridder, Arwin
    [J]. EUROPEAN UROLOGY, 2015, 67 (03) : 577 - 588
  • [4] Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/ml
    Al-Azab, Rami
    Toi, Ants
    Lockwood, Gina
    Kulkarni, Girish S.
    Fleshner, Neil
    [J]. UROLOGY, 2007, 69 (01) : 103 - 107
  • [5] New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives
    Albisinni, Simone
    Biaou, Ibrahim
    Marcelis, Quentin
    Aoun, Fouad
    De Nunzio, Cosimo
    Roumeguere, Thierry
    [J]. BMC UROLOGY, 2016, 16
  • [6] Is There Evidence of a Relationship between Benign Prostatic Hyperplasia and Prostate Cancer? Findings of a Literature Review
    Alcaraz, Antonio
    Hammerer, Peter
    Tubaro, Andrea
    Schroder, Fritz H.
    Castro, Ramiro
    [J]. EUROPEAN UROLOGY, 2009, 55 (04) : 864 - 875
  • [7] Alishahi S, 2002, J ROY COLL SURG EDIN, V47, P422
  • [8] The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction
    Andersson, Karl-Erik
    Boedtkjer, Donna B.
    Forman, Axel
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2017, 9 (01) : 11 - 27
  • [9] Effect of Dutasteride on the Risk of Prostate Cancer.
    Andriole, Gerald L.
    Bostwick, David G.
    Brawley, Otis W.
    Gomella, Leonard G.
    Marberger, Michael
    Montorsi, Francesco
    Pettaway, Curtis A.
    Tammela, Teuvo L.
    Teloken, Claudio
    Tindall, Donald J.
    Somerville, Matthew C.
    Wilson, Timothy H.
    Fowler, Ivy L.
    Rittmaster, Roger S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (13) : 1192 - 1202
  • [10] Antunes-Lopes T, 2018, UROLOGY